Document Detail

Dual antiplatelet therapy for primary and secondary prevention.
MedLine Citation:
PMID:  23147438     Owner:  NLM     Status:  In-Data-Review    
The concomitant use of aspirin and an ADP receptor (P2Y12) blocker, also known as dual antiplatelet therapy (DAPT), has been extensively investigated as a primary and secondary prevention strategy in an effort to reduce the risk of cardiovascular events. In this manuscript the authors review the current guideline recommendations for DAPT and discuss the scientific data that supports these recommendations. Reported are also the scientific knowledge gaps and how future studies are likely to delineate these issues. Incremental knowledge is not likely to be an alternative to individualized care provided by the astute clinician to his patient. In consideration for prescribing DAPT (drug, dosage and duration) the clinician will have to weigh the potential benefits (reduction in death from cardiovascular causes, nonfatal myocardial infarction, and nonfatal stroke) and risks (severe or life-threatening bleeding) for each and every patient.
A P Mathur; A H Waller; S Dhruvakumar; V Mazza; C Gerula; J Maher; M Klapholz; E Kaluski
Related Documents :
23360768 - Effect of morbid obesity on in-hospital mortality and coronary revascularization outcom...
24587478 - Poststroke atrial fibrillation: cause or consequence?: critical review of current views.
11065228 - Effects of prolonged caffeine consumption on cardiac contractile function in rats.
13928608 - Calcium flux in the mammalian ventricular myocardium.
11108768 - Metalloproteinase inhibition reduces thrombolytic (tissue plasminogen activator)-induce...
20798368 - Correlation of echocardiographic findings with cerebral infarction in elderly adults: t...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Minerva cardioangiologica     Volume:  60     ISSN:  0026-4725     ISO Abbreviation:  Minerva Cardioangiol     Publication Date:  2012 Dec 
Date Detail:
Created Date:  2012-11-13     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0400725     Medline TA:  Minerva Cardioangiol     Country:  Italy    
Other Details:
Languages:  eng     Pagination:  611-28     Citation Subset:  IM    
Division of Cardiology, Department of Medicine, University Hospital and New Jersey Medical School, Newark, NJ, USA -
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Heart failure: molecular, genetic and epigenetic features of the disease.
Next Document:  Long-term patient benefit with biodegradable polymer biolimus eluting stent.